• Subscribe
  • Magazine
  • Videos
  • Advertise
  • About Us
  • Smart Water Summit
  • Wastewater Summit
    • Recent Quotes
    My Watchlist
    Indicators
    WaterWorld Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    ANI Pharma Inc (NQ: ANIP )

    63.56 +1.11 (+1.79%)
    Streaming Delayed Price Updated: 9:46 AM EDT, Aug 30, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Headline News about ANI Pharma Inc

    < Previous 1 2 3 Next >
    ANIP Stock Earnings: ANI Pharmaceuticals Beats EPS, Beats Revenue for Q2 2024
    ANIP stock results show that ANI Pharmaceuticals beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024. 
    Via InvestorPlace
    NVIDIA To Rally Around 19%? Here Are 10 Top Analyst Forecasts For Wednesday
    Via Benzinga
    Nasdaq Records Worst Session Since April With Nvidia Plunging 7%: Dow Jones Sees Modest Gains Amid Mixed Market Close
    Via Benzinga
    Topics Stocks
    Exposures US Equities
    Why Is Alimera Sciences (ALIM) Stock Up 77% Today?
    Alimera Sciences stock is up on Monday as investors react to a $5.50 per share acquisition offer for ALIM from ANI Pharmaceuticals. 
    Via InvestorPlace
    Generics Player ANI Pharmaceuticals Strengthens Rare Disease Segment With $380M Alimera Sciences Deal
    ANI Pharmaceuticals to acquire Alimera Sciences for $5.50 per share in cash, plus a contingent value right of up to $0.50 per share. The transaction is valued at $381 million and is expected to close... 
    Via Benzinga
    Evaluating ANI Pharmaceuticals: Insights From 5 Financial Analysts
    Via Benzinga
    Expert Outlook: ANI Pharmaceuticals Through The Eyes Of 4 Analysts
    Via Benzinga
    Earnings Scheduled For February 29, 2024
    Companies Reporting Before The Bell • Frontline (NYSE:FRO) is expected to report quarterly earnings at $0.46 per share on revenue of $276.19 million. 
    Via Benzinga
    ANIP Stock Earnings: ANI Pharmaceuticals Beats EPS, Beats Revenue for Q1 2024
    ANIP stock results show that ANI Pharmaceuticals beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024. 
    Via InvestorPlace
    Alphabet, Dover And 2 Other Stocks Insiders Are Selling
    The Nasdaq 100 closed lower by around 1.5% on Friday. Investors, meanwhile, focused on some notable insider trades. 
    Via Benzinga
    Drug Maker Organon Stock Scores Relative Strength Upgrade
    In a welcome move, drug maker Organon stock saw its Relative Strength Rating rise from 66 to 71 on Wednesday. 
    Via Investor's Business Daily
    ANI Pharmaceuticals's Earnings Outlook
    Via Benzinga
    Truist Securities Maintains Buy Rating for ANI Pharmaceuticals: Here's What You Need To Know
    Via Benzinga
    Why Is Generic Drug Player ANI Pharmaceuticals Stock Trading Lower Today?
    ANI Pharmaceuticals Inc's (NASDAQ: ANIP) third-quarter revenues were $131.8 million, up 57.3% Y/Y, beating the  
    Via Benzinga
    Expert Ratings for ANI Pharmaceuticals
    Via Benzinga
    Analyst Expectations for ANI Pharmaceuticals's Future
    Via Benzinga
    What 4 Analyst Ratings Have To Say About ANI Pharmaceuticals
    Via Benzinga
    Where ANI Pharmaceuticals Stands With Analysts
    Via Benzinga
    7 A-Rated Biotech Stocks for Your August Buy List
    Investing in biotech stocks means accepting a long R&D window, but the rewards when your A-rated biotech stocks come through are huge. 
    Via InvestorPlace
    Looking Into ANI Pharmaceuticals's Return On Capital Employed
    Via Benzinga
    Stocks Reverse Gains Ahead Of Slew Of Inflation Data
    Stocks are lower this afternoon, as investors await a deluge of inflation data amid a rally for the banking sector. 
    Via Talk Markets
    Why ANI Pharmaceuticals Stock Is Soaring Today
    ANI Pharmaceuticals Inc's (NASDAQ: ANIP) Q1 revenues were $106.8 million, +65.6% Y/Y, beating the  
    Via Benzinga
    12 Health Care Stocks Moving In Monday's Pre-Market Session
    Via Benzinga
    Earnings Preview For ANI Pharmaceuticals
    Via Benzinga
    ANI Pharmaceuticals Earnings Perspective: Return On Capital Employed
    Via Benzinga
    ANI Pharmaceuticals's Return On Capital Employed Overview
    Via Benzinga
    Why Tredegar Shares Are Trading Lower By 15%? Here Are Other Stocks Moving In Monday's Mid-Day Session
    Gainers Trevena, Inc. (NASDAQ: TRVN) shares surged 170% to $1.74 after the company announced the approval of OLINVYK in China. 
    Via Benzinga
    Guggenheim Creates Bullish Pitch For ANI Pharma On Progress With Cortrophin Launch
    Via Benzinga
    Benzinga's Top Ratings Upgrades, Downgrades For March 1, 2023
    Via Benzinga
    Organon Stock Scores Market Leadership With Jump To 83 RS Rating
    Organon sees its Relative Strength Rating reach the 80-plus level. 
    Via Investor's Business Daily
    < Previous 1 2 3 Next >
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.